Home / Healthcare / 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Pipeline Review, H1 2016

70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Pipeline Review, H1 2016

Published: Jun 2016 | No Of Pages: 42 | Published By: Global Markets Direct

70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Pipeline Review, H1 2016’, provides in depth analysis on 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1)
- The report reviews 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding 70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) Overview 6
Therapeutics Development 7
70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Products under Development by Stage of Development 7
70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Products under Development by Therapy Area 8
70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Products under Development by Indication 9
70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Products under Development by Companies 12
70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 16
Assessment by Molecule Type 17
70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Companies Involved in Therapeutics Development 18
ArQule, Inc. 18
Astex Pharmaceuticals, Inc. 19
Eddingpharm 20
Merck KGaA 21
PharmAust Limited 22
Phoenix Biotechnology, Inc. 23
Sentinel Oncology Limited 24
70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Drug Profiles 25
AT-13148 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
EDP-317 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
M-2698 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
monepantel - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
PBI-05204 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Small Molecule To Inhibit S6K1 For Breast Cancer - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Small Molecules to Inhibit S6K for Cancer - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Dormant Projects 34
70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Discontinued Products 35
70-kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Featured News & Press Releases 36
Jan 29, 2016: PharmAust Limited Announced Quarterly Report & Company Update For the period ended 31 December 2015 36
Nov 26, 2015: PharmAust Appoints GenScript to Complete Further Pre-Clinical Validation for Phase II Trial 37
Jan 17, 2013: Cancer Research UK And Cancer Research Technology Launches Phase I Clinical Trial With AT13148 To Treat Several Cancer Types 37
Jan 16, 2013: Astex Pharma Announces Cancer Research UK And Cancer Research Technology Initiate AT13148 Clinical Trial To Treat Several Cancer Types 38
Jul 10, 2012: Experimental Drug Could Treat Different Cancers, New Research Says 39
Jan 22, 2010: ACT BIOTECH Announces FDA Acceptance Of IND For ACTB1003, A First-in-Class Anti-Cancer Therapeutic 40
Oct 18, 2007: Astex Drug Candidates To Be Featured At The 2007 AACR-NCI-EORTC International Conference 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42

Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Products under Development by Companies, H1 2016 13
Assessment by Monotherapy/Combination Products, H1 2016 14
Number of Products by Stage and Mechanism of Action, H1 2016 15
Number of Products by Stage and Route of Administration, H1 2016 16
Number of Products by Stage and Molecule Type, H1 2016 17
Pipeline by ArQule, Inc., H1 2016 18
Pipeline by Astex Pharmaceuticals, Inc., H1 2016 19
Pipeline by Eddingpharm, H1 2016 20
Pipeline by Merck KGaA, H1 2016 21
Pipeline by PharmAust Limited, H1 2016 22
Pipeline by Phoenix Biotechnology, Inc., H1 2016 23
Pipeline by Sentinel Oncology Limited, H1 2016 24
Dormant Projects, H1 2016 34
Discontinued Products, H1 2016 35

Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Early Stage Products, H1 2016 11
Assessment by Monotherapy/Combination Products, H1 2016 14
Number of Products by Stage and Mechanism of Actions, H1 2016 15
Number of Products by Stage and Routes of Administration, H1 2016 16
Number of Products by Stage and Molecule Type, H1 2016 17

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +